There is increasing evidence that genetic variability can play an important role in inter individual response to medication. Variants of genes have been reported to modulate the response to drugs that are used in heart failure such as beta-blockers and diuretics. However their impact on outcome is yet to be established and it is likely that many other as yet undiscovered variants are likely to also have a significant impact. In this study, we will utilize a large established “population pharmacogenetics” platform to elucidate the impact of genetic variants on the drug response and outcome in a cohort of patients identified to have heart failure. Investigating how genetic information can enhance the pharmacological management of heart failure is inextricably linked to understanding the molecular genetic basis of CHF itself as clearly the targets for intervention are both the established and yet to be determined molecular pathways involved in its patho-aetiology.
This study plans to investigate both existing pathways but also create a discovery platform for new pathways which may serve as targets for novel interventions. The outcome of our study may help to customize drug prescribing for patients with heart failure to improve efficacy tolerability and safety.